Project Details
Description
PROJECT NARRATIVE
“Triple negative” breast cancer (TNBC) is a subtype of breast cancer that spreads aggressively and often leads
to metastasis and death; it is difficult to treat because it does not respond to current molecularly-targeted
drugs. TIMP2 is a natural human protein with two anticancer activities: (1) it inhibits an enzyme involved in
TNBC metastasis, and (2) it binds to a cell surface receptor to inhibit TNBC growth. We propose to develop a
new cancer drug, based on TIMP2, with improved capability to inhibit both metastasis and tumor growth,
providing a new therapy to improve survival for patients with TNBC.
Status | Active |
---|---|
Effective start/end date | 3/1/21 → 2/28/23 |
Funding
- National Cancer Institute: $290,242.00
- National Cancer Institute: $336,617.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.